GlassScriptPhysician profile
Elisa Park
NPI 1477931186
$4,312.49
in general payments reported to CMS, 2019-2025
21 companies · $30.66 in 2025
The $30.66 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $377 · 2021: $971 · 2022: $1,723 · 2023: $1,142 · 2024: $69.47 · 2025: $30.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,242.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $775.34 | 2020-2023 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $607.15 | 2020-2023 | Auryxia |
| Fresenius USA Marketing, INC. | $553.66 | 2020-2023 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $427.42 | 2021-2024 | |
| Calliditas Therapeutics US INC. | $299.99 | 2022-2023 | Tarpeyo |
| Amgen INC. | $225.98 | 2021-2025 | Tavneos, Epogen, Parsabiv |
| Vifor Pharma, INC. | $219.32 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $182.54 | 2021-2023 | Jynarque |
| Horizon Therapeutics Plc | $169.31 | 2020-2022 | |
| Opko Pharmaceuticals, LLC | $132.00 | 2020-2023 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $127.21 | 2022-2023 | Acthar |
| Travere Therapeutics, INC. | $117.13 | 2022-2023 | |
| Baxter Healthcare | $95.81 | 2022 | |
| Aurinia Pharma U.S., INC. | $69.60 | 2022-2023 | Lupkynis |
| Glaxosmithkline, LLC. | $69.07 | 2023-2024 | Benlysta |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $66.10 | 2020-2025 | Mounjaro, Zepbound |
| Ani Pharmaceuticals, INC. | $55.77 | 2023 | Purified Cortrophin Gel |
| Novo Nordisk INC | $45.60 | 2022 | |
| Ardelyx, INC. | $32.59 | 2023 | Ibsrela |
| Ultragenyx Pharmaceutical INC. | $21.80 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elisa Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.